We are live on ! Find out more
CNST

Constellation Pharmaceuticals, Inc.
CNST

Delisted

CNST was delisted on the 14th of July, 2021.

99 hedge funds and large institutions have $1.25B invested in Constellation Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 43 increasing their positions, 25 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

290% more call options, than puts

Call options by funds: $1.98M | Put options by funds: $509K

72% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 25

14% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 21

0% more funds holding in top 10

Funds holding in top 10: 1212 (0)

1% less funds holding

Funds holding: 10099 (-1)

31% less capital invested

Capital invested by funds: $1.8B → $1.25B (-$549M)

Holders
99
Holders Change
-1
Holders Change %
-1%
% of All Funds
2.18%
Holding in Top 10
12
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.26%
New
24
Increased
43
Reduced
25
Closed
21
Calls
$1.98M
Puts
$509K
Net Calls
+$1.48M
Net Calls Change
-$370K
Name Holding Trade Value Shares
Change
Change in
Stake
PS
1
Peter Svennilson
$190M +$1.45M +41,674 +0.7%
VA
2
VR Adviser
New York
$126M +$140M +4,016,873 New
ACA
3
Avoro Capital Advisors
New York
$115M
Wellington Management Group
4
Wellington Management Group
Massachusetts
$73.6M +$13.8M +396,604 +20%
BCLSI
5
Bain Capital Life Sciences Investors
Massachusetts
$69.3M -$21.6M -620,000 -22%
CAM
6
Cormorant Asset Management
Massachusetts
$64.1M -$9.04M -259,979 -11%
GPP
7
Great Point Partners
Connecticut
$62.2M +$29.3M +842,380 +74%
TG
8
TRV GP
Massachusetts
$48.2M -$52.1M -1,500,000 -49%
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$48M +$35.7M +1,026,158 +205%
ROTUOC
10
Regents of the University of California
California
$47.1M -$8.69M -250,000 -14%
Fidelity Investments
11
Fidelity Investments
Massachusetts
$42M -$8.59M -246,951 -16%
BlackRock
12
BlackRock
New York
$41.3M +$7.86M +226,117 +21%
Victory Capital Management
13
Victory Capital Management
Texas
$41.1M +$45.4M +1,306,321 +58,085%
Vanguard Group
14
Vanguard Group
Pennsylvania
$31.7M +$1.95M +56,007 +6%
CC
15
Casdin Capital
New York
$30.8M -$8.09M -232,734 -19%
DM
16
Deerfield Management
New York
$30M +$14M +404,100 +73%
GTC
17
Ghost Tree Capital
New York
$20.4M +$2.59M +74,500 +13%
T. Rowe Price Associates
18
T. Rowe Price Associates
Maryland
$16.6M +$4.32M +124,292 +31%
Millennium Management
19
Millennium Management
New York
$13.1M -$5.31M -152,831 -27%
Franklin Resources
20
Franklin Resources
California
$11.9M +$4.52M +130,100 +52%
State Street
21
State Street
Massachusetts
$11.1M +$2.69M +77,400 +28%
PHS
22
PFM Health Sciences
California
$9.93M +$11M +315,894 New
Geode Capital Management
23
Geode Capital Management
Massachusetts
$8.98M +$2.07M +59,462 +26%
RSCM
24
Rock Springs Capital Management
Maryland
$7.34M
Northern Trust
25
Northern Trust
Illinois
$7.28M +$1.73M +49,844 +27%

CNST Hedge Fund Activity: Q1 2020 in Review

99 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q1 2020, worth a combined $1.25B — down 31% from $1.8B a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new CNST positions and 21 closed out — a net gain of 3 holders — while 43 added to existing stakes and 25 trimmed.

The largest buyer was Victory Capital Management, adding an estimated $45.4M. The largest seller was TRV GP, cutting an estimated $52.1M.

  • 99 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q1 2020, down from 100 in Q4 2019.
  • Funds reported $1.25B of Constellation Pharmaceuticals, Inc. stock for Q1 2020, down 31% quarter-over-quarter.
  • 24 funds opened new Constellation Pharmaceuticals, Inc. positions in Q1 2020 and 21 closed out, a net change of +3 holders.
  • The largest Constellation Pharmaceuticals, Inc. buyer in Q1 2020 was Victory Capital Management, an estimated $45.4M added.
  • The largest Constellation Pharmaceuticals, Inc. seller in Q1 2020 was TRV GP, an estimated $52.1M sold.

Based on aggregated 13F filings for Q1 2020.